Pivotal clinical trial design of FDA and EMA approved compounds for rare seizure conditions.

<p>Pivotal clinical trial design of FDA and EMA approved compounds for rare seizure conditions.</p

Cumulative number of approved non-orphan antiepileptic drugs (◆) illustrating the year of first licensing or the first mention of clinical use in a country of Europe, the United States, or Japan (adapted from [31]).

<p>Cumulative number of US orphan drug designations (○) and approvals (●). Cumulative number of orphan drug designations (□) and approvals (■) in the EU.</p

Compounds for rare seizure conditions designated or approved by the FDA and EMA.

<p>Compounds for rare seizure conditions designated or approved by the FDA and EMA.</p

Time to approval of compounds intended to treat orphan epileptic conditions.

<p>Lines indicate means.</p